Despite the above limitations, higher post-TACE sTIM-3 levels in complete responders may be attributed to the greater extent of tumor infiltration by TIM-3+ T lymphocytes in patients with better response to treatment. The gene discussed is HAVCR2; the disease is neoplasm.